Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Novacyt   /   Novacyt de volgende biotech raket!

Aandeel Novacyt PSE:ALNOV.FR, FR0010397232

Laatste koers (eur) Verschil Volume
0,577   0,000   (0,00%) Dagrange 0,571 - 0,585 93.095  

Novacyt de volgende biotech raket!

Volgen
70.768 Posts
Pagina: «« 1 ... 10 11 12 13 14 ... 3539 »» | Laatste | Omlaag ↓
  3. [verwijderd] 17 september 2018 22:27
    Ik zie dat deze, voor wat het waard is, hier nog niet is geplaatst:

    NOVACYT PARTNERS WITH APPLIED MICROARRAYS
    IN ASSAY DESIGN

    US partnership to facilitate the design and optimisation for
    customised microarray assays

    Paris, France and Camberley, UK – 13 September 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its molecular testing division, Primerdesign Ltd. (Primerdesign), has partnered with Applied Microarrays, Inc. (AMI), a company that specialises in providing customised microarrays and manufacturing point-of-care (POC) and high throughput DNA and protein arrays, to offer comprehensive single nucleotide polymorphism (SNP) assay development.

    Primerdesign will play an integral part in designing probes for AMI and their customers. The microarray based molecular diagnostic tests developed under this partnership will play a crucial role in the early diagnosis, as well as improve patient management and outcome. Primerdesign has thirteen years’ experience in molecular assay design and this partnership highlights the division’s pivotal role in assay development as it grows its relationships with leading diagnostic companies.

    Working together, Primerdesign and AMI can provide a full suite of assay development services from probe designs, through to assay optimisation, regulatory and ultimately high volume manufacturing of SNP microarrays for use in POC as well as laboratory-based settings.

    Alastair Malcolm, President & CEO of AMI, commented:
    “Novacyt is an expert in molecular diagnostic assay design and development and I am pleased to enter this strategic partnership to develop customised microarray based diagnostic tests. Through working with Primerdesign, we have been impressed with their assay development expertise and ability to deliver a high quality service in a timely manner. I am confident that our partnership will help us to deliver multiplexed probe based diagnostic and detection with better diagnosis and improved patient outcomes.”

    Graham Mullis, Group CEO of Novacyt, added:
    “I am delighted that we are entering into a partnership with AMI. This partnership significantly expands our offering and geographic reach as we continue to expand our molecular products business.
    “I am also pleased to see continued progress in our business-to-business opportunities converting into commercial partnerships. We are increasingly becoming the partner of choice for molecular diagnostic companies and I look forward to updating shareholders with further partnerships like this.”

    Financial terms of the agreement have not been disclosed.
  5. [verwijderd] 26 september 2018 09:23
    Paris, France and Camberley, UK – 26 September 2018 – Novacyt (ALTERNEXT: ALNOV; AIM: NCYT), an international specialist in clinical diagnostic products, today announces unaudited financial results for the six months ended 30 June 2018.
    Unaudited revenues were broadly flat at €7.0m following a strong performance by the Primerdesign and Lab21 Products divisions, offset by lower sales from NOVAprep®. Group gross margin increased to 64% (61% H1 2017) and the EBITDA loss was €0.5m. Excluding NOVAprep®, the Group achieved EBITDA breakeven.

    Financial highlights
    • Consolidated unaudited Group revenue of €7.0m, marginal increase compared to H1 2017
    o Primerdesign revenue increased 15% (18% CER) to €3m
    o Lab21 revenue increased 3% (6% CER) to €3.4m
    o NOVAprep® revenue of €0.6m versus €1.1m in H1 2017
    • Group revenue increased 1% at CER compared with H1 2017 as a result of a previously announced decision to re-optimise the NOVAprep® product, exacerbated by supply issues
    • Excluding the impact of NOVAprep®, Group revenue increased 8% (11% at CER)
    • Gross profit increased from €4.3m to €4.5m representing a three-percentage point increase from 61% to 64%
    • EBITDA loss of €0.5m in H1 2018 was broadly similar to the same period in 2017 as a result of higher gross profit offset by NOVAprep® losses
    • Excluding the impact of NOVAprep® EBITDA was at break-even for the first half
    • Novacyt had €2.1m in cash and cash equivalents at the end of 30 June 2018

    Het volledige bericht:

    novacyt.com/wp-content/uploads/2018/0...

    Als ik het goed zie 2 miljoen verlies in een half jaar en nog 2 miljoen in kas.
    Reken maar uit.
    Hopelijk komt er geen financiering a la Esperite of Visiomed uit de hoge hoed bij dit aandeel want dan gaat het ver naar beneden.
  6. forum rang 10 DeZwarteRidder 26 september 2018 09:34
    quote:

    Show_Me_The_Money schreef op 26 september 2018 09:23:

    Paris, France and Camberley, UK – 26 September 2018 – Novacyt (ALTERNEXT: ALNOV; AIM: NCYT), an international specialist in clinical diagnostic products, today announces unaudited financial results for the six months ended 30 June 2018.
    Unaudited revenues were broadly flat at €7.0m following a strong performance by the Primerdesign and Lab21 Products divisions, offset by lower sales from NOVAprep®. Group gross margin increased to 64% (61% H1 2017) and the EBITDA loss was €0.5m. Excluding NOVAprep®, the Group achieved EBITDA breakeven.

    Financial highlights
    • Consolidated unaudited Group revenue of €7.0m, marginal increase compared to H1 2017
    o Primerdesign revenue increased 15% (18% CER) to €3m
    o Lab21 revenue increased 3% (6% CER) to €3.4m
    o NOVAprep® revenue of €0.6m versus €1.1m in H1 2017
    • Group revenue increased 1% at CER compared with H1 2017 as a result of a previously announced decision to re-optimise the NOVAprep® product, exacerbated by supply issues
    • Excluding the impact of NOVAprep®, Group revenue increased 8% (11% at CER)
    • Gross profit increased from €4.3m to €4.5m representing a three-percentage point increase from 61% to 64%
    • EBITDA loss of €0.5m in H1 2018 was broadly similar to the same period in 2017 as a result of higher gross profit offset by NOVAprep® losses
    • Excluding the impact of NOVAprep® EBITDA was at break-even for the first half
    • Novacyt had €2.1m in cash and cash equivalents at the end of 30 June 2018

    Het volledige bericht:

    novacyt.com/wp-content/uploads/2018/0...

    Als ik het goed zie 2 miljoen verlies in een half jaar en nog 2 miljoen in kas.
    Reken maar uit.
    Hopelijk komt er geen financiering a la Esperite of Visiomed uit de hoge hoed bij dit aandeel want dan gaat het nog veel verder naar beneden.
    Dat laatste gaat 100% zeker gebeuren.
  12. [verwijderd] 22 november 2018 12:51
    Was hier al even niet geweest maar sinds mijn vorige post nog maar eens 25% van de koers af in 2 maanden tijd.

    En de kas raakt leger en leger.
    Binnenkort het bericht dat men "financiering" "krijgt" van het een of andere vage equity line fonds. Die gaan in ruil voor flinke korting hun winst maken door stukken z.s.m. te dumpen op de beurs boven de koers die zij betalen. Dan is het helemaal einde verhaal over de ruggen van de bestaande aandeelhouders.

    Het zag er zo mooi en veelbelovend uit maar wat een treurig verhaal is dit toch geworden.

  19. [verwijderd] 27 november 2018 10:31

    Novacyt Signs $3.0M Diagnostics Supply Agreement with Genesis Diagnostics
    November 27, 2018 02:00 AM Eastern Standard Time

    PARIS & CAMBERLEY, England--(BUSINESS WIRE)--Regulatory News:

    Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its molecular testing division, Primerdesign Ltd. (Primerdesign), has signed an exclusive supply agreement worth a minimum of $3 million with Genesis Diagnostics, a US-based full service diagnostic laboratory that offers clinical diagnostic testing, oral fluid drug testing and services focused on drug monitoring, substance abuse programmes, infectious disease, and personalised medicine.

    Primerdesign will develop and supply 384 well plate molecular assay panels for respiratory, women’s health, sexually transmitted, wound and urinary tract infections for Genesis Diagnostics to use in its clinical service laboratory based in Langhorne, Pennsylvania.

    Under the terms of the agreement, Primerdesign will be appointed the exclusive product manufacturer of the panel for a minimum of five years. The supply of product is expected to commence in early 2019 and Genesis Diagnostics will purchase minimum quantities of product to the value of $600,000 per year.
70.768 Posts
Pagina: «« 1 ... 10 11 12 13 14 ... 3539 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee